Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 1621 AL 1635

CSF α-Synuclein and Tau as Biomarkers for Dementia With Lewy Bodies: A Systematic Review and Meta-analysis

Zhang Q, Li J, Quan W, Liu L, Qin Y, Pei X, Su H, Xu J, Chen J.

Alzheimer Dis Assoc Disord. 2022 Oct-Dec 01;36(4):368-373. doi: 10.1097/WAD.0000000000000516. Epub 2022 Sep 12.

Recent progress in the graphene-based biosensing approaches for the detection of Alzheimer's biomarkers

Rouhi N, Akhgari A, Orouji N, Nezami A, Rahimzadegan M, Kamali H.

J Pharm Biomed Anal. 2023 Jan 5;222:115084. doi: 10.1016/j.jpba.2022.115084. Epub 2022 Sep 28.

Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers

Duong MT, Wolk DA.

Curr Neurol Neurosci Rep. 2022 Nov;22(11):689-698. doi: 10.1007/s11910-022-01232-4. Epub 2022 Oct 3.

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Weiner MW, Veitch DP, Miller MJ, Aisen PS, Albala B, Beckett LA, Green RC, Harvey D, Jack CR Jr, Jagust W, Landau SM, Morris JC, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2023 Jan;19(1):307-317. doi: 10.1002/alz.12797. Epub 2022 Oct 9.

[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]

Popp J, Georgescu D, Bürge M, Mundwiler-Pachlatko E, Bernasconi L, Felbecker A.

Praxis (Bern 1994). 2022;111(13):738-744. doi: 10.1024/1661-8157/a003913.

Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers

Zetterberg H, Schott JM.

Neurology. 2022 Oct 24;99(17):735-736. doi: 10.1212/WNL.0000000000201172.

Cerebrovascular damage in subjective cognitive decline: A systematic review and meta-analysis

Pitti H, Diaz-Galvan P, Barroso J, Badji A, Olofsson JK, Westman E, Ferreira D, Cedres N.

Ageing Res Rev. 2022 Dec;82:101757. doi: 10.1016/j.arr.2022.101757. Epub 2022 Oct 12.

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA.

JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.

The omega-3 index in Alzheimer's disease: Ready for prime time?

Yassine HN.

Am J Clin Nutr. 2022 Dec 19;116(6):1474-1475. doi: 10.1093/ajcn/nqac248.

Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review

Carazo-Barrios L, Cabrera-Maestre A, Alba-Linero C, Gutiérrez-Bedmar M, Garzón-Maldonado FJ, Serrano V, de la Cruz-Cosme C, García-Casares N.

J Neuroophthalmol. 2023 Mar 1;43(1):116-125. doi: 10.1097/WNO.0000000000001673. Epub 2022 Oct 18.

Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Roveta F, Cermelli A, Boschi S, Ferrandes F, Grassini A, Marcinnò A, Spina M, Rubino E, Borsello T, Vercelli A, Rainero I.

J Alzheimers Dis. 2022;90(4):1381-1393. doi: 10.3233/JAD-220515.

Editorial: Blood-Based Biomarkers for Alzheimer's Disease: Are We There Yet?

Tariot P.

J Prev Alzheimers Dis. 2022;9(4):565-566. doi: 10.14283/jpad.2022.88.

Is Mitochondria DNA Variation a Biomarker for AD?

Gao R, Ma SL.

Genes (Basel). 2022 Oct 3;13(10):1789. doi: 10.3390/genes13101789.

[Imaging of neuropathology by PET tracers]

Harada R.

Nihon Yakurigaku Zasshi. 2022;157(6):453-457. doi: 10.1254/fpj.22061.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias